MOLECULAR TEMPLATES INC (MTEM) Stock Price, Quote, News and Summary

Company Profile

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 62 full-time employees. The company went IPO on 2005-02-04. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).

Company Info

MOLECULAR TEMPLATES INC

9301 Amberglen Blvd, Suite 100

Austin TEXAS 78729 US

CEO: Eric E. Poma

Employees: 62

Company Website: https://www.mtem.com/

Investor Relations: https://www.mtem.com/investors

Phone: 15128961555